Clinical characteristic of patients with EGPA. Values are n (%) unless otherwise specified.
| Clinical Characteristics | Activity, n = 9 | Remission, n = 32 |
|---|---|---|
| Women | 8 (88.9) | 21 (65.6) |
| Age, yrs, mean ± SD | 54.4 ± 5.8 | 56.0 ± 12.7 |
| Asthma | 9 (100) | 30 (93.8) |
| Constitutional symptoms | 8 (88.9) | 28 (87.5) |
| Arthralgia/myalgia | 9 (100) | 25 (78.1) |
| Skin | 6 (66.7) | 18 (56.3) |
| Peripheral neuropathy | 8 (88.9) | 24 (75.0) |
| Pulmonary disease | 7 (77.8) | 18 (56.3) |
| Heart | 3 (33.3) | 7 (21.9) |
| Gastrointestinal tract | 0 (0) | 2 (6.3) |
| Kidney | 1 (11.1) | 9 (28.1) |
| ENT | 7 (77.8) | 29 (90.6) |
| MPO-ANCA | 5 (55.6) | 12 (37.5) |
| BVAS, median (range) | 12 (4–21) | 0 |
| Glucocorticoids | 6 (66.7) | 32 (100) |
| Immunosuppressive agents | 3 (33.3) | 15 (46.9) |
| Azathioprine, n | 2 | 11 |
| Methotrexate, n | 1 | 4 |
EGPA: eosinophilic granulomatosis with polyangiitis; MPO: myeloperoxidase; ANCA: antineutrophil cytoplasmic antibodies; BVAS: Birmingham Vasculitis Activity Score.